Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GSK · against 1,216 other Healthcare companies
Ranked #335 of 1,217 · scores higher than 72% of peers
Bars: peers in each 10-point band of the growth score121 peers with a growth score of 70–79, including GSK · Click a bar to see the companies
Mainly thanks to its earnings per share growth, which is stronger than most Healthcare peers.
| Metric | GSK | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 1,243 reported | 4.1% | 6.1% | 43% | 33% | |
| Earnings per share growthHigher is better · 682 reported | 121.9% | 9.7% | 88% | 33% | |
| 3-year revenue growthHigher is better · 1,192 reported | 3.7% | 5.8% | 40% | 33% |
| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 464M USD | 100 | 53 | |
| 3 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 3 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 3 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 335 | 25.3B HKD (≈$3.2B) | 72 | 57 | |
| 335 | 8.7B CNY (≈$1.2B) | 72 | 77 | |
| 335 | 70.2B JPY (≈$477M) | 72 | 59 | |
| 335 | 540.4B BRL (≈$97.3B) | 72 | 64 | |
| 335 | 97.5B USD | 72 | 67 | |
| 335 | 162.93T ARS (≈$162.9B) | 72 | 63 | |
| 335 | 118.0B INR (≈$1.4B) | 72 | 68 | |
| 335 | 2.4B CHF (≈$2.7B) | 72 | 59 | |
| 335 | 1.3B BRL (≈$238M) | 72 | 77 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score